Phase II Study to Determine the Efficacy of OSI-211 (Liposomal Lurtotecan) Given on Days 1, 2 & 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer

Inclusion Criteria:

- Confirmed recurrent small cell lung cancer.

- One prior treatment of chemotherapy.

- At least three weeks since last chemotherapy treatment and recovery from any related
side effects.

- At least three weeks since last chest radiotherapy and at least 10 days since head
irradiation and recovery from acute side effects.

- At least one target tumor less than or equal to 20 mm (or less than or equal to 10 mm
on spiral CT-scan).

- If a patient has had previous documented Central Nervous System (CNS) involvement,
only controlled disease is acceptable.

Exclusion Criteria:

- Superior vena cava syndrome.